Svitlana Tyekucheva
Harvard University
H-index: 33
North America-United States
Top articles of Svitlana Tyekucheva
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract PO3-13-02: Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and … | Cancer Research | Svitlana Tyekucheva Thayane Crestani Michail Ignatiadis Patrick Neven Marco Colleoni | 2024/5/2 |
Abstract PO2-16-02: RBsig gene-expression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial | Cancer Research | Matteo Benelli Svitlana Tyekucheva Thayane Crestani Michail Ignatiadis Patrick Neven | 2024/5/2 |
Abstract P01: Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition | Blood Cancer Discovery | Kiyomi Mashima Nicholas Moore Mariia Mikhaleva Anna Petráčková Samantha Shupe | 2024/3/4 |
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL | Blood advances | Inhye E Ahn Danielle M Brander Yue Ren Yinglu Zhou Svitlana Tyekucheva | 2024/1/3 |
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia | Leukemia | Christine E Ryan Danielle M Brander Paul M Barr Svitlana Tyekucheva Liam R Hackett | 2023/4 |
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome | Hematological Oncology | MS Davids KA Rogers N Jain S Tyekucheva Y Ren | 2023/6 |
Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition | Blood | Kiyomi Mashima Mariia Mikhaleva Stacey M Fernandes Samantha J Shupe Svitlana Tyekucheva | 2023/11/28 |
The prostate stromal transcriptome in aggressive and lethal prostate cancer | Molecular Cancer Research | Chaoran Ma Yinglu Zhou Giuseppe Nicolò Fanelli Konrad H Stopsack Michelangelo Fiorentino | 2023/3/1 |
SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL. | Jennifer Leigh Crombie Inhye E Ahn Svitlana Tyekucheva Reid Merryman David Christopher Fisher | 2023/6/1 | |
Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients | Blood | Mariia Mikhaleva Svitlana Tyekucheva Kiyomi Mashima Stacey M Fernandes Matthew S Davids | 2023/11/28 |
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia | Journal of Clinical Oncology | Benjamin L Lampson Aditi Gupta Svitlana Tyekucheva Kiyomi Mashima Anna Petráčková | 2023/2/10 |
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative. | Elisa Agostinetto Christos Sotiriou Michail Ignatiadis Thayane Antoniolli Crestani David Venet | 2023/6/1 | |
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples | Blood | Jasneet Kaur Khalsa Justin Cha Filippo Utro Aishath Naeem Ishwarya Murali | 2023/8/3 |
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors | Blood Cancer Journal | Deepti Gadi Stephen P Martindale Pui Yan Chiu Jasneet Khalsa Pei-Hsuan Chen | 2023/2/2 |
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance | Blood Advances | Aishath Naeem Filippo Utro Qing Wang Justin Cha Mauno Vihinen | 2023/5/9 |
A harmonized resource of integrated prostate cancer clinical,-omic, and signature features | Scientific Data | Teemu D Laajala Varsha Sreekanth Alex C Soupir Jordan H Creed Anni S Halkola | 2023/7/5 |
Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies | Blood | Roberta Santos Azevedo Francesca Morelli Kiyomi Mashima Rayan Fardoun Svitlana Tyekucheva | 2023/11/28 |
curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource | bioRxiv | Teemu D Laajala Varsha Sreekanth Alex Soupir Jordan Creed Federico CF Calboli | 2023/1/19 |
Cross-study replicability in cluster analysis | Statistical science: a review journal of the Institute of Mathematical Statistics | Lorenzo Masoero Emma Thomas Giovanni Parmigiani Svitlana Tyekucheva Lorenzo Trippa | 2023/5 |
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS) | Hematological Oncology | IE Ahn DM Brander Y Ren Y Zhou S Tyekucheva | 2023/6 |
